SEC Filing Summary: Helius Medical Technologies, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Helius Medical Technologies, Inc. (HSDT) on April 4, 2025, reporting events occurring on March 31, 2025. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC. The filing addresses regulatory compliance issues regarding continued listing standards.
Key Financial Metrics
The filing references the Company's Annual Report on Form 10-K for the year ended December 31, 2024, noting that stockholders' equity has fallen below the $2.5 million threshold required by Nasdaq Listing Rule 5550(b)(1). The text does not provide specific values for revenue, profit, cash flow, margins, or debt levels.
Material Changes and Listing Status
- Stockholders' Equity Deficiency: On March 31, 2025, Nasdaq notified the Company of non-compliance with the minimum stockholders' equity requirement due to equity falling below $2.5 million.
- Minimum Bid Price Deficiency: The Company previously failed to meet the minimum bid price requirement for 30 consecutive business days. The initial 180-day compliance period expired on February 7, 2025.
- Delisting Risk: Due to non-compliance with the $5,000,000 minimum stockholders' equity initial listing requirement, the Company was initially ineligible for an additional extension period regarding the bid price deficiency.
- Extension Granted: Following a hearing on March 18, 2025, Nasdaq granted an extension until June 30, 2025, to regain compliance with both the Minimum Bid Price Requirement and the Stockholders' Equity Requirement.
Outlook and Management Commentary
The Company states that the notices have no immediate impact on the listing of its common stock, which will continue to trade under the symbol "HSDT." Management intends to seek to regain compliance with the required standards within the granted extension period ending June 30, 2025. The filing does not contain specific financial guidance or discuss other risks beyond the listing deficiencies.
Investor Verification Checklist
- Verify the exact stockholders' equity figure reported in the Form 10-K for the year ended December 31, 2024.
- Monitor the Company's progress toward meeting the $2.5 million equity and minimum bid price requirements by the June 30, 2025 deadline.
- Review the Company's capital raising plans or strategic actions intended to restore compliance.
- Confirm that no further delisting notices have been issued subsequent to the April 1, 2025 extension letter.